周二早盘，Viking Therapeutics（VKTX）股价飙升约30%，此前该公司公布了一项令人振奋的试验结果——其实验性减肥注射剂在降低给药频率的情况下，仍能帮助患者有效维持体重下降效果。这一涨幅若得以维持，将创下该股自2024年2月以来的最大单日百分比涨幅。
在这项研究中，从每周给药转为隔周一次的患者，平均维持了最初减重量的90%。而那些转向每月一次维持剂量的患者，平均保留了85%的减重效果——作为对比，安慰剂组仅为约61%。
"疗效数据确实亮眼，但真正让这次发现与众不同的，是采用更少注射次数却依然能保住减重成果这一点，"花旗分析师Geoff Meacham如此点评。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.